The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network-Reference-Cited by-同舟云学术

The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): A joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network

Published:2013-09 Issue:9 Volume:37 Page:1070-1076
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Tan Daryl,Kim Kihyun,Kim Jin Seok,Eom Hyeon-Seok,Teoh Gerrard,Ong Kiat Hoe,Goh Yeow Tee,Durie Brian G.M.,Chng Wee Joo,Lee Jae Hoon

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference42 articles.

1. Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials;Jagannath;Leukemia,2007

2. Bortezomib plus melphalan and prednisolone in elderly untreated patients with multiple myeloma: results of a multicenter phase I/II study;Mateos;Blood,2006

3. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3;Barlogie;Br J Haematol,2007

4. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function;Jagannath;Cancer,2005

5. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bortezomib, Melphalan, and Prednisone With or Without Daratumumab in Transplant-ineligible Asian Patients With Newly Diagnosed Multiple Myeloma: The Phase 3 OCTANS Study;Clinical Lymphoma Myeloma and Leukemia;2023-06

2. MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy;Medical Oncology;2019-07-24

3. Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop;Leukemia & Lymphoma;2018-02-02

4. Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib;Oncology Letters;2017-03-27

5. Myeloma in the Real World: What Is Really Happening?;Clinical Lymphoma Myeloma and Leukemia;2017-03